Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

Multiple myeloma cells are highly proliferative ... associated with ADC therapy is keratopathy, or toxicity to the eye's corneal epithelium, which may lead patients to discontinue ADC treatments.

One of the biggest risk is probably aging, myeloma is more common as people grow older. So the median age at which patients get diagnosed with myeloma is about 68/69 years. So it's still ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...